About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
Subtipat i resistències del virus de la hepatitis C
Quasispècies del virus de la hepatitis E
Exosomes hepàtics en malalties hepàtiques i tumors hepàtics
Identificació, caracterització i variabilitat d’agents virals per seqüenciació massiva, Next Generation Sequencing (NGS)
Serveis o tecnologies rellevants
Seqüenciació Sanger i massiva (NGS)
Extracció i amplificació àcids nucleics
Filogènia molecular disseny primers
Tècniques de Biologia Molecular
Gradients per aïllament i estudi d'exosomes en plasma i femta
Citometria de Flux
Resposta immune cel·lular
Cultius
Clonació, expressió de proteïnes recombinants en cultius cel·lulars
Bioinformàtica
IP: Juan Ignacio Esteban Mur, Josep Quer Sivila
IP: Maria Francesca Cortese Collaborators: Maria Jose Herrero Mata, Elena Vargas Accarino, Maria Buti Ferret, Ariadna Rando Segura, Jordi Llaneras Artigues, Adriana Palom Agusti, Francesc Rudilla Salvador, David Tabernero Caellas, Beatriz Pacín Ruiz Funding agency: Instituto de Salud Carlos III Funding: 220000 Reference: PI23/01065 Duration: 01/01/2024 - 30/06/2028
IP: Juan Manuel Pericas Pulido Collaborators: Alba Maria Jiménez Masip, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 65000 Reference: CM23/00251 Duration: 02/01/2024 - 01/01/2026
IP: Ariadna Rando Segura Collaborators: David Tabernero Caellas Funding agency: Gilead Sciences, S.L.U. Funding: 49961 Reference: GLD22/00080 Duration: 28/02/2023 - 31/08/2026
IP: Ariadna Rando Segura Collaborators: Maria Buti Ferret, David Tabernero Caellas, Maria Francesca Cortese Funding agency: Gilead Sciences, S.L.U. Funding: 27000 Reference: GILEAD/HEPATITIS/2022/RANDO Duration: 22/02/2023 - 30/03/2026
The CHANCE study analyzes the outcomes of nearly 1,000 patients at 63 liver transplant centers and identifies which patients with the most severe forms of the disease may benefit from transplantation.
The grants support projects led by Drs. María José Buzón, María Buti, Elena Élez, and Maria Vieito.
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
